Designing a high-density fed-batch, E. coli-based strategy to produce recombinant GLP-1 cuts upstream production costs 20–30%.
Continuous processing can get products to market about 12 months faster than batch processing, according to a 2022 paper by the FDA. Understandably, the drive to transition to continuous bioprocessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results